Logo image of BIOA

BIOAGE LABS INC (BIOA) Stock Fundamental Analysis

NASDAQ:BIOA - Nasdaq - US09077V1008 - Common Stock - Currency: USD

4.38  +0.11 (+2.58%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to BIOA. BIOA was compared to 195 industry peers in the Pharmaceuticals industry. BIOA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. BIOA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year BIOA has reported negative net income.
BIOA Yearly Net Income VS EBIT VS OCF VS FCFBIOA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 -20M -40M -60M

1.2 Ratios

BIOA has a Return On Assets (-24.44%) which is comparable to the rest of the industry.
The Return On Equity of BIOA (-26.83%) is better than 66.67% of its industry peers.
Industry RankSector Rank
ROA -24.44%
ROE -26.83%
ROIC N/A
ROA(3y)-135.29%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BIOA Yearly ROA, ROE, ROICBIOA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 0 -200 -400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BIOA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BIOA Yearly Profit, Operating, Gross MarginsBIOA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

The number of shares outstanding for BIOA has been increased compared to 1 year ago.
The debt/assets ratio for BIOA has been reduced compared to a year ago.
BIOA Yearly Shares OutstandingBIOA Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 10M 20M 30M
BIOA Yearly Total Debt VS Total AssetsBIOA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 100M 200M 300M

2.2 Solvency

An Altman-Z score of 2.06 indicates that BIOA is not a great score, but indicates only limited risk for bankruptcy at the moment.
With a decent Altman-Z score value of 2.06, BIOA is doing good in the industry, outperforming 68.72% of the companies in the same industry.
A Debt/Equity ratio of 0.00 indicates that BIOA is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.00, BIOA is in line with its industry, outperforming 58.97% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.06
ROIC/WACCN/A
WACCN/A
BIOA Yearly LT Debt VS Equity VS FCFBIOA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

A Current Ratio of 13.68 indicates that BIOA has no problem at all paying its short term obligations.
BIOA has a better Current ratio (13.68) than 86.67% of its industry peers.
BIOA has a Quick Ratio of 13.68. This indicates that BIOA is financially healthy and has no problem in meeting its short term obligations.
BIOA has a better Quick ratio (13.68) than 86.67% of its industry peers.
Industry RankSector Rank
Current Ratio 13.68
Quick Ratio 13.68
BIOA Yearly Current Assets VS Current LiabilitesBIOA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 100M 200M 300M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for BIOA have decreased by -6.13% in the last year.
EPS 1Y (TTM)-6.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, BIOA will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.66% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y75.68%
EPS Next 2Y30.98%
EPS Next 3Y19.66%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BIOA Yearly Revenue VS EstimatesBIOA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2025 2026 2027 500K 1M 1.5M 2M 2.5M
BIOA Yearly EPS VS EstimatesBIOA Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 -2 -4 -6 -8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

BIOA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year BIOA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BIOA Price Earnings VS Forward Price EarningsBIOA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BIOA Per share dataBIOA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

BIOA's earnings are expected to grow with 19.66% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.98%
EPS Next 3Y19.66%

More info and screens

0

5. Dividend

5.1 Amount

BIOA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOAGE LABS INC

NASDAQ:BIOA (6/5/2025, 3:27:13 PM)

4.38

+0.11 (+2.58%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-06 2025-05-06/amc
Earnings (Next)N/A N/A
Inst Owners65.17%
Inst Owner Change2.82%
Ins Owners3.63%
Ins Owner Change0%
Market Cap157.02M
Analysts46.67
Price Target5.78 (31.96%)
Short Float %5.19%
Short Ratio6.46
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)20.17%
Min EPS beat(2)7.1%
Max EPS beat(2)33.23%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-10.53%
EPS NQ rev (1m)7.5%
EPS NQ rev (3m)35.89%
EPS NY rev (1m)8%
EPS NY rev (3m)34.64%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 108.22
P/FCF N/A
P/OCF N/A
P/B 0.5
P/tB 0.5
EV/EBITDA N/A
EPS(TTM)-2.34
EYN/A
EPS(NY)-2.34
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.04
BVpS8.74
TBVpS8.74
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -24.44%
ROE -26.83%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-135.29%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 13.68
Quick Ratio 13.68
Altman-Z 2.06
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)133.82%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-6.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y75.68%
EPS Next 2Y30.98%
EPS Next 3Y19.66%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-61.56%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-19.47%
EBIT Next 3Y-17.84%
EBIT Next 5YN/A
FCF growth 1Y-38.26%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-37.9%
OCF growth 3YN/A
OCF growth 5YN/A